These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1551178)

  • 21. What is the effect of adjusting epirubicin doses for body surface area?
    Dobbs NA; Twelves CJ
    Br J Cancer; 1998 Sep; 78(5):662-6. PubMed ID: 9744507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
    Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
    Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
    Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
    Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the validity of a population pharmacokinetic model for epirubicin.
    Ralph LD; Sandstrom M; Twelves C; Dobbs NA; Thomson AH
    Br J Clin Pharmacol; 2006 Jul; 62(1):47-55. PubMed ID: 16842378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic drug interaction between epirubicin and interferon-alpha-2b in serum and red blood cells.
    Bandak S; Czejka M; Schüller J; Schernhammer E
    Arzneimittelforschung; 1995 Feb; 45(2):212-5. PubMed ID: 7710452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of epirubicin in an oily contrast medium after intravenous and intrahepato-arterial administration in liver cancer: a preliminary report.
    Lee K; Chan K; Leung WT; Leung NW; Ho S; Chan M; Lau CC; Tao M; Lau WY; Shiu W
    Eur J Drug Metab Pharmacokinet; 1992; 17(3):221-6. PubMed ID: 1337040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.
    Jakobsen P; Bastholt L; Dalmark M; Pfeiffer P; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS; Mouridsen HT
    Cancer Chemother Pharmacol; 1991; 28(6):465-9. PubMed ID: 1934250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.
    Eksborg S; Hardell L; Bengtsson NO; Sjödin M; Elfsson B
    Med Oncol Tumor Pharmacother; 1992; 9(2):75-80. PubMed ID: 1341719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Br J Clin Pharmacol; 2004 Jun; 57(6):764-72. PubMed ID: 15151522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
    Venturini M; Lunardi G; Del Mastro L; Vannozzi MO; Tolino G; Numico G; Viale M; Pastrone I; Angiolini C; Bertelli G; Straneo M; Rosso R; Esposito M
    J Clin Oncol; 2000 May; 18(10):2116-25. PubMed ID: 10811677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
    Müller HJ; Grubert M; Hilger R; Richly H; Port R; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):575-7. PubMed ID: 12503820
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacokinetics of epirubicin hydrochloride long-circulating thermosensitive liposomes in rat plasma].
    Wu Y; Zhang FC; Wu C; Mei XG; Lü WL
    Yao Xue Xue Bao; 2010 Mar; 45(3):365-70. PubMed ID: 21351514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats.
    Shin DH; Park SH; Jeong SW; Park CW; Han K; Chung YB
    Arch Pharm Res; 2014 Dec; 37(12):1599-606. PubMed ID: 25373308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic interaction between 4'-epidoxorubicin and the multidrug resistance reverting agent quinine.
    Czejka M; Bandak S; Simon D; Schüller J; Weiss C; Schernhammer E
    Z Naturforsch C J Biosci; 1995; 50(7-8):565-70. PubMed ID: 7546045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics of epirubicin in cancer patients].
    Ohno T; Shimoyama T; Kimura K; Yamada H
    Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
    Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.